Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
Authors:
- Steven R. FeldmanSFSteven R. Feldman
- Alexa Boer KimballAKAlexa Boer Kimball
- Gerald G. KruegerGKGerald G. Krueger
- J. Michael WoolleyJWJ. Michael Woolley
- Deepa LallaDLDeepa Lalla
- Angelika JahreisAJAngelika Jahreis
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 53 (5) , 887-889
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporinBritish Journal of Dermatology, 2001
- Health-related Quality of Life in Patients with Psoriasis and Atopic Dermatitis Measured with SF-36, DLQI and a Subjective Measure of Disease ActivityActa Dermato-Venereologica, 2000
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Quality of life assessments in dermatologySeminars in Cutaneous Medicine and Surgery, 1998
- Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasisBritish Journal of Dermatology, 1998
- The Application of Multiple Quality-of-Life Instruments in Individuals with Mild-to-Moderate PsoriasisPharmacoEconomics, 1996
- POPULATION-BASED EPIDEMIOLOGIC STUDY OF PSORIASIS WITH EMPHASIS ON QUALITY OF LIFE ASSESSMENTDermatologic Clinics, 1996
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A reviewJournal of Clinical Epidemiology, 1992